EDNRA
Endothelin-1 receptor
As of the edition of 20 October 2026, EDNRA (endothelin-1 receptor, UniProt P25101) has 15 drugs tested at it and 10 companies on the list, 2 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P25101
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Lungs and airways; Heart and blood vessels; Urinary and reproductive; Cancer; Pregnancy and women's health; Skin and connective tissue; Inherited and neonatal; Immune system
- Registered trials of its drugs
- 313
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 6 |
| Active | 1 |
| Went quiet | 1 |
| Stopped | 6 |
| Withdrawn from market | 1 |
| Total | 15 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Bosentan | Marketed | Phase 4 | none listed |
| Macitentan | Marketed | Phase 4 | Ends 2031 |
| Ambrisentan | Marketed | Phase 4 | none listed |
| Zibotentan | Active | Phase 3 | none listed |
| Sitaxentan | Withdrawn from market | Phase 3 | none listed |
| Atrasentan | Marketed | Phase 4 | Ends 2030 |
| Aprocitentan | Marketed | Phase 3 | Ends 2038 |
| BQ-123 | Stopped | Phase 2 | none listed |
| Clazosentan | Marketed | Phase 3 | none listed |
| Darusentan | Stopped | Phase 3 | none listed |
| Tezosentan | Stopped | Phase 3 | none listed |
| Nebentan | Stopped | Phase 2 | none listed |
12 of 15 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 3 |
| Engaged | 3 |
| Undetermined | 2 |
| Total on the list | 10 |
The other 7 companies at EDNRA
In the product10 companies in all; 7 are not named here, and no score is.
See the 10 companies at EDNRA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.